New hope for rare lung cancer: lorlatinib targets resistant tumors

NCT ID NCT04621188

Ongoing Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests the drug lorlatinib in 54 people with advanced ROS1-positive non-small cell lung cancer whose cancer has stopped responding to initial targeted therapy. Lorlatinib is designed to overcome resistance and reach the brain. Researchers will measure how many patients' tumors shrink or disappear after 8 weeks of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lorlatinib
What this could lead to: If successful, lorlatinib could become a new treatment option for people with ROS1-positive lung cancer whose cancer has stopped responding to initial therapy.
What could go wrong: This is a small, early-phase trial with only 54 participants and no comparison group. Results may not confirm benefit, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER METASTATIC

Contacts and locations

Show contact details

Locations

AP-HP Hopital Tenon - Pneumologie

Paris, 75020, France
AP-HP Hôpital Ambroise Paré

Boulogne, 92104, France
AP-HP Hôpital Cochin

Paris, 75014, France
Angers - CHU

Angers, France
Annecy - CH

Annecy, France
Antony - Hôpital privé

Antony, France
Avignon - CH

Avignon, France
Bordeaux - CHU

Bordeaux, France
Bordeaux - Institut Bergonie

Bordeaux, France
Bordeaux - Polyclinique

Bordeaux, France
CHRU Grenoble

Grenoble, France
CHU Bretonneau

Tours, 37044, France
CHU Toulouse - Pneumologie

Toulouse, France
Caen - CHU Côte de Nacre

Caen, 14000, France
Centre Hospitalier - Pneumologie

Le Mans, 72000, France
Centre Hospitalier Intercommunal de Créteil

Créteil, 94000, France
Centre Hospitalier de la Côte Basque

Bayonne, 64100, France
Centre Hospitalier du Pays d'Aix

Aix-en-Provence, 13616, France
Centre Léon Bérard

Lyon, 69373, France
Centre Paul Papin

Angers, 49055, France
Chauny - CH

Chauny, France
Cholet - CH

Cholet, France
Clermont-Ferrand - CHU

Clermont-Ferrand, France
Colmar - CH

Colmar, France
Dijon - CRLCC

Dijon, France
GRH Mulhouse Sud-Alsace

Mulhouse, France
Hôpital Calmette

Lille, 59037, France
Hôpital Foch

Suresnes, 92151, France
Institut Paoli Calmettes

Marseille, 13273, France
Lyon - URCOT

Pierre-Bénite, France
Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France
Rouen - CHU

Rouen, France
Valenciennes - Clinique

Valenciennes, France
Vandoeuvre-lès-Nancy - CHU

Vandœuvre-lès-Nancy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.